International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-3 doi: 10.5281/zenodo.7945371
Original Article
Tru-Cut Biopsy versus Fine Needle Aspiration Cytology in Diagnosis of Early Breast Cancer
 ,
Published
May 17, 2023
Abstract
Background: Breast lump is a common symptom among women, and it may be indicative of benign or malignant conditions. The clinical and histopathological profile of breast lumps can provide insights into the epidemiology and risk factors of breast cancer. This retrospective study aimed to investigate the clinical and histopathological characteristics of breast lumps in women. Methods: We analysez 80 women who presented with breast lumps in the Dept of Surgery, Srinivas Institute of Medical Sciences and Research Centre. The patients' age, lump size, site of the lump, consistency, involved quadrant, skin changes, nipple discharge, nipple retraction, presence of pain, and axillary lymphadenopathy were recorded. The patients were divided into two groups: benign and malignant, based on histopathological examination. Results: The ROC analysis findings suggest that both FNAC and TRUCUT Biopsy are effective in detecting malignant tumors. FNAC had an accuracy of 90.6%, sensitivity of 92.31% and specificity of 88.89%, while TRUCUT Biopsy had an accuracy of 97.2%, sensitivity of 100% and specificity of 94.34%. Both tests showed significant association with the study groups, with p<0.05. The AUC values for FNAC and TRUCUT Biopsy were 0.906 and 0.972, respectively, indicating that both tests have high accuracy in detecting malignant tumors. The 95% CI for the AUC values were 0.820 to 0.960 for FNAC and 0.908 to 0.996 for TRUCUT Biopsy. Conclusion: Taking into account the benefits and limitations of both techniques, we argue that Tru-Cut should be preferred over FNAC for the diagnosis of palpable breast lumps with FNAC being reserved for definitely benign lesions. Freehand Tru-Cut detects more breast carcinomas as compared to FNAC in palpable breast lumps. and correctly categorizes borderline/ inadequate breast lumps on FNAC into benign & malignant categories, thus reducing indeterminate results and treatment delays. It can therefore be used as an alternative to open biopsy.
Recommended Articles
Loading Image...
Volume-4, Issue-3
Citations
657 Views
408 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved